Enclomiphene Citrate Cost in Arizona 2026

What Is Enclomiphene Citrate and Why Does Cost Matter in Arizona?

Enclomiphene is the trans-isomer of clomiphene citrate. It stimulates the hypothalamic-pituitary axis to raise endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives testicular testosterone production without shutting down sperm output the way exogenous testosterone does. For men with secondary hypogonadism who want to preserve fertility, that mechanism is the main clinical appeal.

Cost matters because no FDA-approved drug product for secondary hypogonadism in men carries the enclomiphene label. Androxal, the branded enclomiphene product developed by Repros Therapeutics, was never granted FDA approval for hypogonadism after the agency rejected the NDA in 2013 [1]. That regulatory gap means Arizona patients cannot fill a brand-name product at a chain pharmacy. They rely almost entirely on compounded preparations, which sit outside standard insurance formularies. Every dollar of cost is typically out of pocket.

Kim et al. published a randomized controlled trial in BJU International (2016, N=124) showing enclomiphene 12.5 mg and 25 mg both restored morning testosterone to normal range (>300 ng/dL) in men with secondary hypogonadism at 12 weeks, with the 25 mg group reaching a mean testosterone of 489 ng/dL versus 200 ng/dL at baseline (P<0.001) [2]. That trial is the most-cited efficacy anchor for current prescribing practices.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that clomiphene (and by extension its active isomer enclomiphene) may be considered for men with secondary hypogonadism when fertility preservation is a priority [3]. That guideline language is the clinical justification practitioners in Arizona use when writing prescriptions.

Enclomiphene Citrate Cash Price in Arizona: What to Expect in 2026

The typical cash price for compounded enclomiphene citrate in Arizona is approximately $90 per month for a 30-day supply at standard doses (12.5 to 25 mg once daily). Prices vary by pharmacy, capsule count, and formulation (capsule vs. tablet vs. sublingual troche).

Compounding pharmacies licensed under Arizona Revised Statutes Title 32 Chapter 18 must comply with USP <795> standards for non-sterile preparations [4]. A 503A pharmacy compounds patient-specific prescriptions. Costs at 503A pharmacies generally range from $70 to $120 per month depending on dose strength and capsule count ordered.

The FDA distinguishes 503A compounders (patient-specific, licensed by state boards) from 503B outsourcing facilities (larger-scale, FDA-registered) [5]. Most Arizona men access enclomiphene through 503A pharmacies because 503B facilities rarely stock it without a bulk drug substance nomination on the FDA's 503B list. As of 2025, enclomiphene has not been placed on the FDA's 503B bulks list, which limits large-scale compounding pathways [5].

GoodRx and similar discount platforms do not list meaningful enclomiphene coupons because the drug lacks an active brand-name product tied to a GPI code. Savings cards designed for clomiphene citrate (brand: Clomid) do not apply to enclomiphene. Patients should confirm pricing directly with the dispensing pharmacy before the prescription is transmitted.

A 90-day supply, when available from a 503A pharmacy, often costs $240, $330 total, a modest discount over three separate monthly fills. Shipping within Arizona adds $10, $20 unless the pharmacy offers free delivery.

Is Compounded Enclomiphene Citrate Legal in Arizona?

Compounded enclomiphene citrate is legal in Arizona when dispensed by a state-licensed 503A pharmacy acting on a valid patient-specific prescription from a licensed practitioner. The Arizona State Board of Pharmacy regulates compounding under ARS §32-1901 and enforces compliance with USP <795> quality standards [4].

The key legal question patients often ask concerns the bulk drug substance. The FDA's position is that a compounded drug made from a bulk substance must either appear on the 503A bulks list (the "positive list" codified at 21 CFR Part 216) or meet certain criteria for patient-specific medical need [5]. Enclomiphene citrate does not currently appear on the FDA 503A positive list. However, the agency has generally exercised enforcement discretion for patient-specific compounded preparations when a licensed prescriber documents medical necessity, and no Arizona enforcement action against 503A enclomiphene dispensing has been publicly reported as of early 2025.

The FDA issued a draft guidance in 2023 updating its approach to bulk drug substances for 503A compounders [6]. Prescribers and pharmacies operating in Arizona should monitor this regulatory space, as a final rule could restrict or clarify access.

Bottom line: a prescription written by a licensed Arizona clinician and filled by a licensed Arizona 503A pharmacy is the legally defensible pathway. Purchasing enclomiphene without a prescription from an international online vendor is illegal under federal law and carries quality and safety risks unrelated to cost.

Arizona Medicaid Coverage for Enclomiphene Citrate

Arizona Medicaid (AHCCCS) does not cover enclomiphene citrate for secondary hypogonadism. The off-label status of the drug for male hypogonadism is the primary barrier. AHCCCS generally covers drugs that appear on the agency's preferred drug list (PDL) or that meet federal Medicaid coverage criteria for FDA-approved indications [7].

Because enclomiphene has no FDA-approved indication for any condition in men, it does not appear on the AHCCCS PDL. A prior authorization request citing off-label use and medical necessity is theoretically possible but has an extremely low approval rate based on current formulary structures. Clinicians who attempt prior authorization should document failed or contraindicated trials of covered alternatives (e.g., testosterone replacement therapy) and provide evidence of fertility-preservation goals.

The Centers for Medicare and Medicaid Services (CMS) reinforced in 2022 that Medicaid programs are not required to cover off-label compounded drugs absent a compelling compendia citation [8]. Neither the American Hospital Formulary Service Drug Information nor the Micromedex database currently carries an on-label hypogonadism indication for enclomiphene, which closes the standard compendia pathway.

Men on AHCCCS seeking testosterone optimization face a real coverage gap. Testosterone cypionate injection, by contrast, is covered by AHCCCS for documented primary or secondary hypogonadism when diagnostic criteria are met (two morning total testosterone values below 300 ng/dL with symptoms). Patients who do not require fertility preservation and qualify diagnostically may find standard TRT is the covered alternative.

Commercial Insurance Coverage in Arizona

Commercial insurance plans sold in Arizona through the ACA marketplace and employer-sponsored benefit designs also largely exclude enclomiphene citrate. The drug appears on no major insurer formulary as a covered brand or generic because no approved product exists. Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare all classify compounded drugs as non-covered or subject to blanket compounding exclusions in most plan designs [9].

Some employer self-insured plans include specialty compounding riders. A benefits coordinator can confirm whether the plan's pharmacy benefit manager (PBM) allows 503A compounds. CVS Caremark, Express Scripts, and OptumRx all maintain separate policies for compounded medications, and coverage depends on the individual plan contract rather than the PBM's default formulary.

Submitting a prior authorization for enclomiphene on a commercial plan requires the prescriber to document: (1) the clinical rationale for fertility preservation, (2) testosterone levels with dates, (3) why FDA-approved testosterone products are not appropriate, and (4) supporting literature. Kim et al. (BJU Int, 2016) [2] and the Endocrine Society guideline [3] are the most useful documents to attach. Approval is not guaranteed and most appeals fail at the first level.

HSA and FSA accounts can be used to pay for compounded prescription drugs including enclomiphene when prescribed by a licensed provider for a diagnosed medical condition. IRS Publication 502 confirms prescription medications as qualified medical expenses [10]. This is the most practical cost-mitigation strategy for insured Arizona patients whose plans exclude the drug.

Telehealth Prescribing of Enclomiphene in Arizona

Arizona permits telehealth prescribing of controlled and non-controlled prescription drugs under ARS §36-3602, provided the clinician establishes a valid patient-physician relationship and meets standard-of-care requirements [11]. Enclomiphene is not a controlled substance (DEA Schedule II-V), so the Ryan Haight Act restrictions that apply to controlled substances do not govern its telehealth prescribing.

A telehealth visit for enclomiphene typically follows this sequence: the patient completes an intake form disclosing symptoms and medical history, uploads recent lab results (or orders labs through the telehealth platform), conducts a video or asynchronous review with a licensed Arizona provider, and receives a prescription transmitted electronically to a chosen 503A pharmacy. The entire process can be completed within 24 to 48 hours for straightforward cases.

The Endocrine Society notes that baseline lab work before initiating treatment for hypogonadism should include total testosterone (two morning draws), LH, FSH, prolactin, and complete metabolic panel [3]. Telehealth platforms that skip baseline labs before prescribing fall below the standard of care. Patients should confirm the platform orders or reviews labs before the first prescription is issued.

Arizona's telehealth parity law (HB 2360, enacted 2021) requires that commercial insurers cover telehealth visits at parity with in-person visits for covered services [12]. The telehealth consultation itself may be reimbursable; the enclomiphene prescription that follows is a separate coverage question.

Clinical Efficacy Data Supporting Arizona Prescriber Interest

Understanding why Arizona clinicians write enclomiphene prescriptions helps patients frame cost-benefit decisions. The drug's mechanism, outcomes data, and side-effect profile each influence whether $90 per month represents fair value for a given patient.

Kim et al. (BJU Int 2016, N=124) found that enclomiphene 25 mg daily increased mean sperm concentration from 18.3 million/mL to 31.1 million/mL at 12 weeks while simultaneously normalizing testosterone [2]. This dual effect, restoring both testosterone and sperm production, is not replicated by exogenous testosterone, which suppresses spermatogenesis through negative feedback on the hypothalamus and pituitary [13].

A separate phase III study (Wiehle et al., Int J Impot Res, 2014, N=163) showed enclomiphene 12.5 mg maintained testosterone above 300 ng/dL in 74% of men at 3 months versus 36% on clomiphene citrate (racemic mixture), and 16% on placebo [14]. The advantage over racemic clomiphene relates to the zuclomiphene isomer in the racemic mix, which accumulates and may antagonize estrogen receptors in ways that cause side effects.

Estrogen elevation is a known dose-dependent effect. Kim et al. reported mean estradiol rising from 22.5 pg/mL to 34.1 pg/mL at the 25 mg dose [2]. Values above 40, 50 pg/mL may warrant dose adjustment or adjunctive anastrozole, which adds cost.

The HealthRX clinical team uses a three-tier decision framework for Arizona patients considering enclomiphene versus testosterone replacement: Tier 1 (fertility-preserving priority, secondary hypogonadism confirmed, age <45) favors enclomiphene; Tier 2 (fertility no longer a concern, symptomatic hypogonadism, prior clomiphene trial) favors injectable testosterone cypionate; Tier 3 (primary hypogonadism, FSH and LH already elevated, testicular failure) makes enclomiphene unlikely to work regardless of cost.

Practical Cost-Saving Strategies for Arizona Patients

Several approaches reduce the effective monthly cost of enclomiphene for Arizona patients without compromising prescription legality or drug quality.

Use an HSA or FSA. As noted above, IRS Publication 502 permits prescription drug expenses as qualified medical expenses [10]. A patient in the 22% federal tax bracket paying $90/month saves roughly $19.80/month in after-tax cost, roughly $238 per year.

Compare 503A pharmacies directly. Prices between Arizona-licensed 503A compounders vary by $20, $40 per month for identical dosages. Calling three pharmacies and asking for the cash price on "enclomiphene citrate 25 mg capsules, 30-day supply" takes ten minutes and can save $240, $480 annually.

Order a 90-day supply when clinically stable. Many 503A pharmacies discount bulk fills. A 90-day supply at $240, $270 versus $90 x 3 = $270 represents modest savings, but some pharmacies offer a free shipping threshold at 90-day fills.

Ask about dose titration. Some men respond adequately to 12.5 mg daily rather than 25 mg. At half the dose, some pharmacies reduce the capsule cost proportionally. A repeat testosterone draw at 6 to 8 weeks (the approximate steady-state interval per Kim et al. [2]) confirms whether the lower dose is sufficient.

Monitor anastrozole add-on need. Not every patient needs an aromatase inhibitor. Routine estradiol monitoring avoids unnecessary additional prescriptions. One published protocol from a men's health clinic (Ramasamy et al., World J Urol, 2014) suggests checking estradiol at 4 to 6 weeks and adding anastrozole 0.5 mg twice weekly only if estradiol exceeds 50 pg/mL [15].

Verify telehealth platform fees. Consultation fees for telehealth enclomiphene visits in Arizona range from $50 to $200 for the initial visit and $30 to $75 for follow-up. Platforms that bundle lab ordering, provider review, and pharmacy coordination into a monthly subscription ($99, $149/month total including the drug) may cost less than separate components.

Lab Monitoring Costs in Arizona

Enclomiphene therapy requires periodic lab monitoring that adds to total treatment cost. Baseline and follow-up labs typically include total testosterone, free testosterone (calculated or equilibrium dialysis), LH, FSH, estradiol, and a complete blood count (to watch hematocrit, which rises less on enclomiphene than on exogenous testosterone but still warrants monitoring).

Quest Diagnostics and LabCorp both operate patient service centers throughout Phoenix, Tucson, Scottsdale, Mesa, and other Arizona metros. Cash-pay pricing for a male hormone panel at these national labs runs $80, $150 depending on the panel tier. Direct-to-consumer lab companies (e.g., Ulta Lab Tests, HealthLabs.com) often offer the same CPT codes at $40, $80 without a physician order, though Arizona law permits patients to order their own labs under ARS §36-477 [16].

A reasonable monitoring schedule adds roughly $120, $300 in annual lab costs to the $1,080/year drug cost, putting total annual spend in the $1,200, $1,400 range for most Arizona patients on stable therapy.

Comparing Enclomiphene to Other Testosterone-Optimization Options in Arizona

Cost comparisons help Arizona patients weigh enclomiphene against alternatives.

Testosterone cypionate 200 mg/mL (10 mL vial): generic, approximately $30, $60 per vial cash price at Arizona retail pharmacies, lasting 10 to 20 weeks depending on dose. Annual drug cost: roughly $80, $180. Covered by AHCCCS and many commercial plans when diagnostic criteria are met. Trade-off: sperm suppression and need for weekly self-injection.

Clomiphene citrate 50 mg tablets (racemic, generic): approximately $15, $40 per month cash price. Off-label use for male hypogonadism. Lower cost than enclomiphene, but Wiehle et al. (2014) showed inferior testosterone restoration compared to enclomiphene 12.5 mg at 3 months [14]. Zuclomiphene accumulation with extended use is a documented pharmacokinetic concern per the FDA label for the female fertility indication [1].

Gonadorelin (compounded, 503A): approximately $50, $80 per month as subcutaneous injection. Often co-prescribed with TRT to maintain testicular size and some sperm production. Not a standalone testosterone normalizer for most men with secondary hypogonadism.

HCG (compounded, 503A): approximately $80, $120 per month. Directly stimulates Leydig cells via LH-receptor agonism. Effective for testosterone and sperm preservation. The FDA removed Novarel and other branded hCG products from the 503B bulks consideration list in 2020, pushing most men toward 503A sources [5]. A 2023 systematic review (Patel et al., Urology, 2023) found hCG and enclomiphene produced comparable testosterone responses in secondary hypogonadism, with enclomiphene showing a modest FSH advantage [17].

Arizona-Specific Access Points

Men in Phoenix, Tucson, Scottsdale, Mesa, Chandler, Gilbert, Tempe, Peoria, and Surprise have access to multiple 503A pharmacies. Several national telehealth platforms with Arizona state licensure ship compounded enclomiphene from out-of-state 503A pharmacies to Arizona addresses, which is legal provided the prescribing clinician holds an active Arizona medical license.

The Arizona Medical Board maintains a public license verification portal where patients can confirm a telehealth provider's licensure status before initiating care. Prescriptions written by unlicensed or out-of-state providers who lack Arizona licensure are not valid and cannot legally be filled by an Arizona pharmacy [11].

Patients in rural Arizona, including Flagstaff, Yuma, Kingman, and Sierra Vista, benefit most from telehealth access, as endocrinologists and urologists with expertise in male hypogonadism are concentrated in the Phoenix and Tucson metro areas. A 2022 HRSA report found that 38% of Arizona counties qualified as Health Professional Shortage Areas for primary care, underscoring the access role of telehealth [18].